Company
Chirana T. Injecta Group
Pharmaceutical · Slovakia
Available Indicators
115 indicators for Chirana T. Injecta Group. Each opens with a chart and the full value history.
Cost Per Employee (Local Currency) (EUR per month)yearly 2018-2019Net Profit (EUR mil)yearly 2010-2029ROE (%)yearly 2010-2029Employeesyearly 2018-2019Price/Book Value (P/BV)yearly 2016-2029Price/Earnings (P/E)yearly 2016-2029ROA (%)yearly 2010-2029Total Assets (EUR mil)yearly 2009-2029Book Value Per Share (EUR)yearly 2016-2029Cost Per Employee (USD per month)yearly 2018-2019Dividend Per Share (EUR)yearly 2018-2029Dividends (EUR mil)yearly 2018-2029Dividend Yield (%)yearly 2018-2029Earnings Per Share (EPS) (EUR)yearly 2016-2029Pre-Tax Profit (EUR mil)yearly 2009-2029Earnings Per Share Growth (%)yearly 2017-2029Shareholders' Equity (EUR mil)yearly 2009-2029Book Value Per Share Growth (%)yearly 2017-2029Capital Employed (EUR mil)yearly 2009-2029Capital Expenditures (EUR mil)yearly 2010-2029Capital Expenditures (As % of Sales) (%)yearly 2010-2029Cash & Cash Equivalents (EUR mil)yearly 2009-2029Cash Conversion Cycle (days)yearly 2009-2029Cash Earnings (EUR mil)yearly 2009-2029Cash Earnings Per Share (EUR)yearly 2016-2029Cash Earnings Per Share Growth (%)yearly 2017-2029Change in Working Capital (EUR mil)yearly 2010-2029Cost of Financing (%)yearly 2010-2029Cost of Goods & Services (EUR mil)yearly 2009-2029Current Assets (EUR mil)yearly 2009-2029Current Liabilities (EUR mil)yearly 2009-2029Current Ratioyearly 2009-2029Days Payable Outstanding (days)yearly 2009-2029Days Sales Of Inventory (days)yearly 2009-2029Days Sales Outstanding (days)yearly 2009-2029Depreciation (EUR mil)yearly 2010-2029Dividends Paid (EUR mil)yearly 2019-2029EBIT (EUR mil)yearly 2009-2029EBITDA (EUR mil)yearly 2009-2029EBITDA Growth (%)yearly 2010-2029EBITDA Margin (%)yearly 2009-2029EBIT Growth (%)yearly 2010-2029EBIT Margin (%)yearly 2009-2029Effective Tax Rate (%)yearly 2009-2029Enterprise Value (EV) (USD mil)yearly 2016-2029Equity (EUR mil)yearly 2009-2029Equity Before Minority Interest (EUR mil)yearly 2009-2029EV/Capital Employedyearly 2016-2029EV/EBITyearly 2016-2029EV/EBITDAyearly 2016-2029EV/Free Cash Flowyearly 2016-2029EV/Salesyearly 2016-2029Extraordinary Cost (EUR mil)yearly 2009-2029Financing Cost (EUR mil)yearly 2009-2029Financing Income (EUR mil)yearly 2020-2029Free Cash Flow (EUR mil)yearly 2010-2029Free Cash Flow Per Share (EUR)yearly 2016-2029Free Cash Flow Yield (%)yearly 2016-2029Goodwill (EUR mil)yearly 2009-2029Gross Margin (%)yearly 2009-2029Gross Profit (EUR mil)yearly 2009-2029Intangible Assets (EUR mil)yearly 2009-2029Inventories (EUR mil)yearly 2009-2029Issuance Of Debt (EUR mil)yearly 2010-2029Liabilities (EUR mil)yearly 2009-2029Long-Term Debt (EUR mil)yearly 2009-2029LT Investments & Receivables (EUR mil)yearly 2009-2029Market Capitalisation (USD mil)yearly 2016-2029Minorities (EUR mil)yearly 2009-2029Minority Interest (EUR mil)yearly 2009-2029Net Change In Cash (EUR mil)yearly 2010-2029Net Debt (EUR mil)yearly 2009-2029Net Debt/EBITDAyearly 2009-2029Net Debt/Equity (%)yearly 2009-2029Net Debt Growth (%)yearly 2010-2029Net Financing Cost (EUR mil)yearly 2009-2029Net Margin (%)yearly 2009-2029Net Profit Avail. to Common (EUR mil)yearly 2009-2029Net Profit Growth (%)yearly 2010-2029Non-Cash Items (EUR mil)yearly 2010-2029Non-Current Assets (EUR mil)yearly 2009-2029Non-Current Liabilities (EUR mil)yearly 2009-2029Number Of Shares (mil)yearly 2016-2029Other Investing Activities (EUR mil)yearly 2010-2029Other LT Liabilities (EUR mil)yearly 2009-2029Other Operating Cost (Income) (EUR mil)yearly 2009-2029Other ST Assets (EUR mil)yearly 2009-2029Other ST Liabilities (EUR mil)yearly 2009-2029Payout Ratio (%)yearly 2018-2029 · quarterly 2021-2027P/FCFyearly 2016-2029Pre-Tax Profit Growth (%)yearly 2010-2029Price/Cash Earnings (P/CE)yearly 2016-2029Property, Plant & Equipment (EUR mil)yearly 2009-2029Quick Ratioyearly 2009-2029Receivables (EUR mil)yearly 2009-2029ROCE (%)yearly 2010-2029Sales (EUR mil)yearly 2009-2029Shareholders' Equity Growth (%)yearly 2010-2029Share Price (EUR)yearly 2016-2029Short-Term Debt (EUR mil)yearly 2009-2029Staff Cost (EUR mil)yearly 2009-2029Staff Cost (As % of Sales) (%)yearly 2009-2029Staff Cost Growth (%)yearly 2010-2029Tax (EUR mil)yearly 2009-2029Total Asset Growth (%)yearly 2010-2029Total Cash From Financing (EUR mil)yearly 2010-2029Total Cash From Investing (EUR mil)yearly 2010-2029Total Cash From Operations (EUR mil)yearly 2010-2029Total Debt (EUR mil)yearly 2009-2029Total Debt Growth (%)yearly 2010-2029Total Revenue Growth (%)yearly 2010-2029Total Revenue Growth (10-year average) (%)yearly 2019-2029Total Revenue Growth (5-year average) (%)yearly 2014-2029Trade Payables (EUR mil)yearly 2009-2029Working Capital (EUR mil)yearly 2009-2029
Whole Company
$19.99 one-off
- ✓ All 115 indicators of Chirana T. Injecta Group
- ✓ Full history, all frequencies
- ✓ Excel download
- ✓ Source & methodology included
Download Excel